Clinical trials: Chemotherapy-Induced Thrombocytopenia, open to volunteers
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Acute Myeloid Leukemia, Neutropenia
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT06245746
- Testing
- umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
Randomized, controlled, open study to evaluate the efficacy and safety of Hetrombopag in the treatment of chemotherapy-induced thrombocytopenia(CIT) in patients with acute myeloid leukemia
- Trial name
- H-CIT-AML (NCT05944211)
- Testing
- Hetrombopag Olamine
- Volunteers
- 72 people
- Sponsor
- RenJi Hospital
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
- Trial name
- N01-A-PICIT-GI (NCT07586813)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Fudan University
Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
The purpose of this clinical trial is to evaluate the safety and efficacy of Romiplostim N01 in patients with solid tumors who are undergoing concurrent/sequential radiotherapy and chemotherapy（combined with/without…
- Conditions
- Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia
- Trial name
- NCT07185893
- Testing
- Human Interleukin-11, Romiplostim N01
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jun wang
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent thrombocytopenia associated with the EAP regimen for…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization, Chemotherapy-Induced Thrombocytopenia
- Trial name
- NCT07848672
- Testing
- rhTPO prophylaxis plus EAP stem-cell mobilization
- Volunteers
- 70 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Chemotherapy-induced Thrombocytopenia, Eltrombopag
Eltrombopag for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
- Trial name
- NCT04600960
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cancer, Cancer-related Problem/Condition
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
Introduction: The number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment.
- Conditions
- Cancer, Cancer-related Problem/Condition, Chemotherapy, Chemotherapy-induced Neutropenia
- Trial name
- AMBeR eBlood (NCT06809101)
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Pomeranian Medical University Szczecin
Thrombocytopenia Chemotherapy Induced
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
This study aims to evaluate the efficacy and safety of Romiplostim N01 for Injection administered as secondary prophylaxis in breast cancer patients with chemotherapy-induced thrombocytopenia (CIT).
- Trial name
- NCT07771881
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
- Trial name
- NCT07063225
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thrombopenia, Cervical Cancer
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer
- Conditions
- Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity
- Trial name
- NCT06745219
- Testing
- herombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy-induced Thrombocytopenia, Herombopag
Herombopag for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors
- Trial name
- NCT05236582
- Testing
- Herombopag
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Single Arm Romiplostim to Prevent CIT
The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy.
- Trial name
- NCT07048249
- Testing
- Romiplostim (AMG-531)
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Gastrointestinal Cancer
A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer
This is a prospective, interventional, open-label, single-arm, multicenter pilot study evaluating the safety, tolerability and maximum tolerated dose (MTD) of splenic Selective Internal Radiation Therapy (SIRT) using TheraSphere…
- Trial name
- SPLENIC-SIRT (NCT07575854)
- Testing
- TheraSphere
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Georges Francois Leclerc
Chemotherapy Induced Thrombocytopenia
A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy
The study consists of five sequential periods: Screening (≤ 4 weeks) Correction phase Maintenance phase (first treatment cycle, Cycle 1) Observation phase (second treatment cycle, Cycle 2) Follow-up Eligible subjects are…
- Trial name
- NCT07408648
- Testing
- hetrombopag 7.5 mg orally once daily
- Volunteers
- 244 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University